During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical ...
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization ...
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition ...
The FDA accepted an sNDA for gedatolisib in PIK3CA-mutant HR+/HER2– advanced breast cancer based on the phase 3 VIKTORIA-1 ...
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results